Replies to post #27373 on Ayala Pharmaceuticals Inc (fka ADXS)

[DewDiligence]

Fair point (eom).

[Easymoneyman00]

Very cheap and cost saving therapy instead of $100,000 a patient treatments. This should be a no brainer for the FDA-and EMA we could probably produce this treatment for half the cost and be the SOC for various cancers! With the cost of treatments going through the roof ADXS could be a life saving alternative to countries that cannot afford pricy treatments that exist in the U.S .

[Funky_Omnivore]

GL,

I fully agree, LM IS better suited in the adjuvant setting than metastatic and also has much less competition in the market in this given setting. Given what we know about allogenic cancer vaccines coupled with heavy competition from PD-1's, I believe Dr. Petit made the conservative call on the AIM2CERV trial even if it does stretch out the trial duration. I have been invested in companies that have strung investors along, and I fully disagree with Roy that that is the intention of this trial. It is simply the trial where AXAL has the highest chances of scoring an FDA win and having a relatively broad application in the marketplace.

[DewDiligence]

Re: Bullish news for a cancer vaccine

IMDZ gets FDA nod for phase-3 trial in STS first-line “maintenance” setting: #msg-135444482.